论文部分内容阅读
AIM:To investigate the effects of antithrombin Ⅲ(AT Ⅲ) injection via the portal vein in acute liver failure.METHODS:Thirty rats were intraperitoneally challenged with lipopolysaccharide(LPS) and D-galactosamine(GalN) and divided into three groups:a control group;a group injected with AT Ⅲ via the tail vein;and a group injected with AT Ⅲ via the portal vein.AT Ⅲ(50 U/kg body weight) was administrated 1 h after challenge with LPS and GalN.Serum levels of inflammatory cytokines and fibrin degradation products,hepatic fibrin deposition,and hepatic mRNA expression of hypoxiarelated genes were analyzed.RESULTS:Serum levels of alanine aminotransferase,tumor necrosis factor-α and interleukin-6 decreased significantly following portal vein AT Ⅲ injection compared with tail vein injection,and control rats.Portal vein AT Ⅲ injection reduced liver cell destruction and decreased hepatic fibrin deposition.This treatment also significantly reduced hepatic mRNA expression of lactate dehydrogenase and heme oxygenase-1.CONCLUSION:A clinically acceptable dose of AT Ⅲ injection into the portal vein suppressed liver damage,probably through its enhanced anticoagulant and antiinflammatory activities.
AIM: To investigate the effects of antithrombin Ⅲ (AT Ⅲ) injection via the portal vein in acute liver failure. METHODS: Thirty rats were intraperitoneally challenged with lipopolysaccharide (LPS) and D-galactosamine (GalN) and divided into three groups: a control a group injected with AT III via the tail vein; and a group injected with AT III via the portal vein. AT III (50 U / kg body weight) was administrated for 1 h after challenge with LPS and GalN.Serum levels of inflammatory cytograms and fibrin degradation products, hepatic fibrin deposition, and hepatic mRNA expression of hypoxiarelated genes were analyzed.RESULTS: Serum levels of alanine aminotransferase, tumor necrosis factor-a and interleukin-6 decreased significantly following portal vein AT Ⅲ injection compared with tail vein injection , and control rats .Portal vein AT Ⅲ injection reduced liver cell destruction and decreased hepatic fibrin deposition. This treatment also significantly reduced hepatic mRNA expression of lactate deh ydrogenase and heme oxygenase-1.CONCLUSION: A clinically acceptable dose of AT III injection into the portal vein suppressed liver damage, probably through its enhanced anticoagulant and antiinflammatory activities.